Bristol-Myers Squibb (BMS) is a prominent global biopharmaceutical company that has been at the forefront of medical innovation for over a century. Established in 1887 and headquartered in New York City, BMS has a rich history of developing life-changing therapies and treatments that span a wide range of therapeutic areas.
The company's mission centers around advancing science to improve patient outcomes. BMS is known for its extensive portfolio of medicines that address critical medical needs, including oncology, immunology, cardiovascular disease, and more. The company's dedication to research and development is evident in its pursuit of innovative treatments and therapies that can transform the lives of patients.
BMS has a strong focus on oncology and has been a key player in developing breakthrough cancer treatments. The company's pipeline includes therapies that target different types of cancer and utilize various approaches, such as immunotherapy and targeted therapies, to enhance treatment options and outcomes for cancer patients.
Through strategic partnerships, BMS collaborates with academic institutions, research organizations, and other biopharmaceutical companies to accelerate the development of novel therapies and treatments. These collaborations aim to leverage collective expertise to address complex medical challenges more effectively.